Published in J Clin Oncol on February 28, 2005
Modified intention to treat reporting in randomised controlled trials: systematic review. BMJ (2010) 1.59
Prostate cancer chemotherapy: emerging from the shadows. J Clin Oncol (2005) 1.10
A Role for OCT4 in Tumor Initiation of Drug-Resistant Prostate Cancer Cells. Genes Cancer (2010) 1.06
New potential anti-cancer agents synergize with bortezomib and ABT-737 against prostate cancer. Prostate (2010) 0.98
Prostate-specific antigen half-life: a new predictor of progression-free survival and overall survival in Chinese prostate cancer patients. Asian J Androl (2009) 0.96
Assessing outcomes in prostate cancer clinical trials: a twenty-first century tower of Babel. Cancer (2008) 0.88
Leptomeningeal metastases from prostate cancer: an emerging clinical conundrum. Clin Exp Metastasis (2009) 0.87
Resistance to paclitaxel increases the sensitivity to other microenvironmental stresses in prostate cancer cells. J Cell Biochem (2011) 0.86
Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II study. Br J Cancer (2007) 0.84
Intermittent docetaxel therapy with estramustine for hormone-refractory prostate cancer in Japanese patients. Int J Clin Oncol (2009) 0.84
Pigment epithelium-derived factor expression prolongs survival and enhances the cytotoxicity of low-dose chemotherapy in castration-refractory prostate cancer. Cell Death Dis (2014) 0.82
Clinical outcomes by relative docetaxel dose and dose intensity as chemotherapy for Japanese patients with castration-resistant prostate cancer: a retrospective multi-institutional collaborative study. Int J Clin Oncol (2013) 0.81
Potentiation of antitumour activity of docetaxel by combination with trastuzumab in a human prostate cancer xenograft model and underlying mechanisms. Br J Cancer (2007) 0.81
A Comprehensive Gene Expression Analysis of Resistance Formation upon Metronomic Cyclophosphamide Therapy. Transl Oncol (2013) 0.81
Weekly, low-dose docetaxel combined with estramustine for Japanese castration-resistant prostate cancer: its efficacy and safety profile compared with tri-weekly standard-dose treatment. Int J Clin Oncol (2013) 0.80
Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC). Invest New Drugs (2007) 0.80
Unmet needs in the prediction and detection of metastases in prostate cancer. Oncologist (2013) 0.78
Efficacy and safety of a modular multi-modal exercise program in prostate cancer patients with bone metastases: a randomized controlled trial. BMC Cancer (2011) 0.78
A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer. Br J Cancer (2006) 0.77
Phase II trial of weekly Docetaxel, Zoledronic acid, and Celecoxib for castration-resistant prostate cancer. Invest New Drugs (2016) 0.76
Phase II study of sequential chemotherapy with docetaxel-estramustine followed by mitoxantrone-prednisone in patients with advanced hormone-refractory prostate cancer. Br J Cancer (2007) 0.75
Surgical castration efficiently delays the time of starting a systemic chemotherapy in castration-resistant prostate cancer patients refractory to initial androgen-deprivation therapy. Prostate Int (2015) 0.75
Randomized phase II trials and prostate-specific antigen endpoints in prostate cancer: much ado about nothing? J Clin Oncol (2005) 0.75
The experience with cytotoxic chemotherapy in metastatic castration-resistant prostate cancer. Urol Clin North Am (2012) 0.75
Clinical Efficacy of TroVax in the Treatment of Progressive Castration-resistant Prostate Cancer. Clin Med Insights Oncol (2012) 0.75
Case report: responses to cabazitaxel in metastatic castration-resistant prostate cancer after extensive docetaxel treatment. Clin Genitourin Cancer (2011) 0.75
Chemotherapy for hormone-resistant prostate cancer: Where are we today? Indian J Urol (2007) 0.75
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol (2013) 4.91
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer (2012) 4.29
Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer. Eur Urol (2008) 3.06
A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res (2007) 2.88
Therapeutic dendritic-cell vaccine for simian AIDS. Nat Med (2002) 2.76
Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med (2004) 2.64
Detecting lung cancer relapse using self-evaluation forms weekly filled at home: the sentinel follow-up. Support Care Cancer (2013) 2.11
A "class action" against the microenvironment: do cancer cells cooperate in metastasis? Cancer Metastasis Rev (2008) 1.91
Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol (2009) 1.83
International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol (2003) 1.83
Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer (2007) 1.73
Establishment of human colon cancer cell lines from fresh tumors versus xenografts: comparison of success rate and cell line features. Cancer Res (2007) 1.69
Platelet microparticles: a potential predictive factor of survival in hormone-refractory prostate cancer patients treated with docetaxel-based chemotherapy. Eur Urol (2008) 1.66
Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival. J Clin Oncol (2012) 1.60
Molecular profiling of patient-derived breast cancer xenografts. Breast Cancer Res (2012) 1.58
Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer. J Clin Oncol (2006) 1.56
Molecular structure of double-minute chromosomes bearing amplified copies of the epidermal growth factor receptor gene in gliomas. Proc Natl Acad Sci U S A (2004) 1.56
The biological meaning of anti-HBC positive result in blood donors: relation to HBV-DNA and to other serological markers. Rev Inst Med Trop Sao Paulo (2003) 1.56
Completely resected non-small cell lung cancer: reconsidering prognostic value and significance of N2 metastases. Ann Thorac Surg (2007) 1.54
Src kinase contributes to the metastatic spread of carcinoma cells. Oncogene (2002) 1.51
The human spleen is a major reservoir for long-lived vaccinia virus-specific memory B cells. Blood (2008) 1.48
Predictive and discriminating three-risk-group prognostic scoring system for staging Hodgkin lymphomas. Cancer (2007) 1.40
Netrin-4 inhibits angiogenesis via binding to neogenin and recruitment of Unc5B. Proc Natl Acad Sci U S A (2008) 1.36
Neutropenia in patients treated with rituximab. N Engl J Med (2003) 1.34
Docetaxel-related side effects and their management. Eur J Oncol Nurs (2009) 1.29
A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer (2009) 1.27
HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process. Cancer (2002) 1.26
Distinctive alterations of invasiveness, drug resistance and cell-cell organization in 3D-cultures of MCF-7, a human breast cancer cell line, and its multidrug resistant variant. Clin Exp Metastasis (2002) 1.22
Molecular mechanisms underlying effects of epidermal growth factor receptor inhibition on invasion, proliferation, and angiogenesis in experimental glioma. Clin Cancer Res (2009) 1.18
Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study. Breast Cancer Res (2012) 1.16
Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study. BJU Int (2010) 1.13
Peripheral benzodiazepine receptor ligands reverse apoptosis resistance of cancer cells in vitro and in vivo. Cancer Res (2002) 1.13
Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand. J Clin Oncol (2005) 1.13
Collecting duct carcinoma of the kidney: a clinicopathological study of 9 cases. J Urol (2003) 1.09
Proliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline-based preoperative chemotherapy. Eur J Cancer (2004) 1.09
Metastatic renal carcinoma: evaluation of antiangiogenic therapy with dynamic contrast-enhanced CT. Radiology (2010) 1.09
Up-regulation of the error-prone DNA polymerase {kappa} promotes pleiotropic genetic alterations and tumorigenesis. Cancer Res (2005) 1.09
A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings. Cancer Immunol Immunother (2010) 1.08
Genetic alterations associated with acquired temozolomide resistance in SNB-19, a human glioma cell line. Mol Cancer Ther (2006) 1.06
Phase II study of lonidamine and diazepam in the treatment of recurrent glioblastoma multiforme. J Neurooncol (2003) 1.06
VEGF polymorphisms are associated with an increasing risk of developing renal cell carcinoma. J Urol (2010) 1.04
Molecular tracing of sexual HIV Type 1 transmission in the southwest border of China. AIDS Res Hum Retroviruses (2008) 1.04
Molecular epidemiological tracing of HIV-1 outbreaks in Hainan island of southern China. AIDS (2009) 1.03
p53 dependent cell-cycle arrest triggered by chemotherapy in xenografted breast tumors. Int J Cancer (2009) 1.01
Nanovectors for anticancer agents based on superparamagnetic iron oxide nanoparticles. Int J Nanomedicine (2007) 1.01
Hormone escape is associated with genomic instability in a human prostate cancer model. Int J Cancer (2009) 1.00
Geraniol, a component of plant essential oils, modulates DNA synthesis and potentiates 5-fluorouracil efficacy on human colon tumor xenografts. Cancer Lett (2004) 1.00
Cancer screening in France: subjects' and physicians' attitudes. Cancer Causes Control (2007) 0.99
Induction of CD8+ regulatory T cells protects macaques against SIV challenge. Cell Rep (2012) 0.99
Dominant effects of CCR2-CCR5 haplotypes in HIV-1 disease progression. J Acquir Immune Defic Syndr (2004) 0.98
Meta-analysis of randomised trials comparing gemcitabine-based doublets versus gemcitabine alone in patients with advanced and metastatic pancreatic cancer. Drugs Aging (2007) 0.98
What is the real impact of bone pain on survival in patients with metastatic hormone-refractory prostate cancer treated with docetaxel? BJU Int (2009) 0.98
Chemotherapy for the treatment of malignant peripheral nerve sheath tumors in neurofibromatosis 1: a 10-year institutional review. Orphanet J Rare Dis (2013) 0.98
Lung cancer and renal insufficiency: prevalence and anticancer drug issues. Lung (2008) 0.98
Strong inhibition of Ewing tumor xenograft growth by combination of human interferon-alpha or interferon-beta with ifosfamide. Oncogene (2002) 0.98
Salvage therapy with bevacizumab-sunitinib combination after failure of sunitinib alone for metastatic renal cell carcinoma: a case series. Eur Urol (2009) 0.97
Prevalence of renal insufficiency in breast cancer patients and related pharmacological issues. Breast Cancer Res Treat (2008) 0.97
Comprehensive staging allows for excellent outcome in patients with localized malignant germ cell tumor of the ovary. Ann Surg (2008) 0.95
Human colorectal tumors and metastases express Gb3 and can be targeted by an intestinal pathogen-based delivery tool. Mol Cancer Ther (2008) 0.95
Circulating macrophage colony stimulating factor as a marker of tumour progression. Eur Cytokine Netw (2002) 0.94
Membrane-type-1 matrix metalloproteinase confers tumorigenicity on nonmalignant epithelial cells. Oncogene (2005) 0.94
Multiple lung cancers prognosis: what about histology? Ann Thorac Surg (2008) 0.93
Distinct responses of xenografted gliomas to different alkylating agents are related to histology and genetic alterations. Cancer Res (2004) 0.92
Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts. J Urol (2003) 0.92
Inhibiting aurora kinases reduces tumor growth and suppresses tumor recurrence after chemotherapy in patient-derived triple-negative breast cancer xenografts. Mol Cancer Ther (2012) 0.91
Enhanced sensitivity to irinotecan by Cdk1 inhibition in the p53-deficient HT29 human colon cancer cell line. Oncogene (2004) 0.91
Prostate-specific antigen kinetics in localized and advanced prostate cancer. BJU Int (2009) 0.90
Confrontation of immunohistochemistry and fluorescent in situ hybridization for the assessment of HER-2/ neu (c-erbb-2) status in urothelial carcinoma. Virchows Arch (2004) 0.90
Identification of multipotent mesenchymal stromal cells in the reactive stroma of a prostate cancer xenograft by side population analysis. Exp Cell Res (2009) 0.90
Clinical relevance of human cancer xenografts as a tool for preclinical assessment: example of in-vivo evaluation of topotecan-based chemotherapy in a panel of human small-cell lung cancer xenografts. Anticancer Drugs (2010) 0.89
Primitive neuroectodermal tumor of the prostate. J Urol (2003) 0.89
Management and outcome of 239 adolescent and adult rhabdomyosarcoma patients. Cancer Med (2013) 0.89
Drug management of prostate cancer: prevalence and consequences of renal insufficiency. Clin Genitourin Cancer (2009) 0.88
Preliminary experience of helical tomotherapy for locally advanced pancreatic cancer. World J Gastroenterol (2009) 0.88
Severe docetaxel overdose induced by pharmacokinetic interaction with dronedarone. J Clin Oncol (2011) 0.88
Detection of lung cancer relapse using self-reported symptoms transmitted via an internet web-application: pilot study of the sentinel follow-up. Support Care Cancer (2014) 0.87
Recurrent iodide mumps after repeated administration of contrast media. Ann Intern Med (2006) 0.87
Preclinical assessment of cisplatin-based therapy versus docetaxel-based therapy on a panel of human non-small-cell lung cancer xenografts. Anticancer Drugs (2009) 0.87
Fifteen-year secondary leukaemia risk observed in 761 patients with Hodgkin's disease prospectively treated by MOPP or ABVD chemotherapy plus high-dose irradiation. Br J Haematol (2002) 0.87
Optimization of iron oxide nanoparticles encapsulation within poly(d,l-lactide-co-glycolide) sub-micron particles. Eur J Pharm Biopharm (2007) 0.86
Variability of bio-clinical parameters in Chinese-origin Rhesus macaques infected with simian immunodeficiency virus: a nonhuman primate AIDS model. PLoS One (2011) 0.86
Expression of genes involved in chemoresistance, proliferation and apoptosis in clinical samples of renal cell carcinoma and correlation with clinical outcome. Anticancer Res (2002) 0.86
Renal insufficiency and anticancer drugs in elderly cancer patients: a subgroup analysis of the IRMA study. Crit Rev Oncol Hematol (2008) 0.86
Gefitinib and chemotherapy combination studies in five novel human non small cell lung cancer xenografts. Evidence linking EGFR signaling to gefitinib antitumor response. Int J Cancer (2007) 0.86
Matched case-control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel-induced onycholysis and cutaneous toxicity of the foot. Cancer (2008) 0.85